(OGN) Organon - Overview
Stock: Contraception, Fertility, Biosimilars, Cardiometabolic, Respiratory, Dermatology
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.58% |
| Yield on Cost 5y | 1.25% |
| Yield CAGR 5y | -11.73% |
| Payout Consistency | 86.5% |
| Payout Ratio | 11.2% |
| Risk 5d forecast | |
|---|---|
| Volatility | 48.5% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.65 |
| Alpha | -59.35 |
| Character TTM | |
|---|---|
| Beta | 0.895 |
| Beta Downside | 0.872 |
| Drawdowns 3y | |
|---|---|
| Max DD | 75.16% |
| CAGR/Max DD | -0.42 |
Description: OGN Organon January 12, 2026
Organon & Co. (NYSE: OGN) is a U.S.–based, globally diversified pharmaceutical company that markets prescription drugs and medical devices across North America, Europe, Asia-Pacific, Latin America, the Middle East, Russia, and Africa. Founded in 1923 and headquartered in Jersey City, New Jersey, the firm operates under the GICS sub-industry “Pharmaceuticals” and generates the majority of its $2.3 billion FY-2023 revenue from the United States, where it sells to wholesalers, hospitals, PBMs, and government programs.
The core of Organon’s growth engine is its women’s-health portfolio, which includes long-acting reversible contraceptives (Nexplanon), the monthly NuvaRing, daily oral pills (Cerazette, Marvelon, Mercilon), and fertility-assisted-reproduction agents such as Follistim AQ, Elonva, and Ganirelix. The global women’s-health market is expanding at a ~6 % CAGR, driven by rising demand for convenient birth-control options and increased access to fertility treatments in emerging economies-trends that directly support Organon’s product mix.
Beyond women’s health, Organon has built a sizable biosimilars franchise (Brenzys, Renflexis, Hadlima) and oncology follow-on products (Ontruzant, Aybintio). The company also markets cholesterol-lowering agents (Zetia, Vytorin, Zocor), antihypertensives (Cozaar, Hyzaar), respiratory therapies (Singulair, Dulera, Asmanex, Nasonex), dermatology, bone-health, and non-opioid pain-management drugs. In FY-2023, biosimilars contributed roughly 12 % of total sales, and Organon’s pipeline includes an adalimumab biosimilar slated for 2025 launch-positioning it to capture part of the $30 billion U.S. biosimilar market that is expected to grow at double-digit rates as patents expire.
Operating in a sector where Medicare Part D pricing reforms and generic competition compress margins, Organon’s 2023 operating margin of 13 % reflects disciplined cost control and a focus on higher-margin specialty brands. For a deeper quantitative view of Organon’s valuation metrics, a quick look at ValueRay’s analyst dashboard can be useful.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 501.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -1.01 > 1.0 |
| NWC/Revenue: 32.07% < 20% (prev 30.68%; Δ 1.40% < -1%) |
| CFO/TA 0.07 > 3% & CFO 949.0m > Net Income 501.0m |
| Net Debt (8.16b) to EBITDA (1.57b): 5.18 < 3 |
| Current Ratio: 1.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (260.7m) vs 12m ago 0.34% < -2% |
| Gross Margin: 55.04% > 18% (prev 0.58%; Δ 5446 % > 0.5%) |
| Asset Turnover: 47.91% > 50% (prev 50.26%; Δ -2.35% > 0%) |
| Interest Coverage Ratio: 2.37 > 6 (EBITDA TTM 1.57b / Interest Expense TTM 516.0m) |
Altman Z'' 1.98
| A: 0.15 (Total Current Assets 4.70b - Total Current Liabilities 2.68b) / Total Assets 13.55b |
| B: 0.10 (Retained Earnings 1.32b / Total Assets 13.55b) |
| C: 0.09 (EBIT TTM 1.22b / Avg Total Assets 13.15b) |
| D: 0.06 (Book Value of Equity 747.0m / Total Liabilities 12.65b) |
| Altman-Z'' Score: 1.98 = BBB |
Beneish M -3.10
| DSRI: 0.87 (Receivables 1.48b/1.73b, Revenue 6.30b/6.41b) |
| GMI: 1.06 (GM 55.04% / 58.26%) |
| AQI: 1.05 (AQ_t 0.56 / AQ_t-1 0.53) |
| SGI: 0.98 (Revenue 6.30b / 6.41b) |
| TATA: -0.03 (NI 501.0m - CFO 949.0m) / TA 13.55b) |
| Beneish M-Score: -3.10 (Cap -4..+1) = AA |
What is the price of OGN shares?
Over the past week, the price has changed by -3.86%, over one month by +1.73%, over three months by +22.68% and over the past year by -43.45%.
Is OGN a buy, sell or hold?
- StrongBuy: 0
- Buy: 2
- Hold: 3
- Sell: 2
- StrongSell: 0
What are the forecasts/targets for the OGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9.4 | 14% |
| Analysts Target Price | 9.4 | 14% |
| ValueRay Target Price | 7 | -15.1% |
OGN Fundamental Data Overview February 03, 2026
P/E Forward = 5.0302
P/S = 0.3524
P/B = 2.4678
Revenue TTM = 6.30b USD
EBIT TTM = 1.22b USD
EBITDA TTM = 1.57b USD
Long Term Debt = 8.78b USD (from longTermDebt, last quarter)
Short Term Debt = 45.0m USD (from shortTermDebt, last quarter)
Debt = 8.83b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.16b USD (from netDebt column, last quarter)
Enterprise Value = 10.38b USD (2.22b + Debt 8.83b - CCE 672.0m)
Interest Coverage Ratio = 2.37 (Ebit TTM 1.22b / Interest Expense TTM 516.0m)
EV/FCF = 18.33x (Enterprise Value 10.38b / FCF TTM 566.0m)
FCF Yield = 5.45% (FCF TTM 566.0m / Enterprise Value 10.38b)
FCF Margin = 8.98% (FCF TTM 566.0m / Revenue TTM 6.30b)
Net Margin = 7.95% (Net Income TTM 501.0m / Revenue TTM 6.30b)
Gross Margin = 55.04% ((Revenue TTM 6.30b - Cost of Revenue TTM 2.83b) / Revenue TTM)
Gross Margin QoQ = 53.50% (prev 54.83%)
Tobins Q-Ratio = 0.77 (Enterprise Value 10.38b / Total Assets 13.55b)
Interest Expense / Debt = 1.45% (Interest Expense 128.0m / Debt 8.83b)
Taxrate = 34.16% (83.0m / 243.0m)
NOPAT = 804.0m (EBIT 1.22b * (1 - 34.16%))
Current Ratio = 1.75 (Total Current Assets 4.70b / Total Current Liabilities 2.68b)
Debt / Equity = 9.74 (Debt 8.83b / totalStockholderEquity, last quarter 906.0m)
Debt / EBITDA = 5.18 (Net Debt 8.16b / EBITDA 1.57b)
Debt / FCF = 14.41 (Net Debt 8.16b / FCF TTM 566.0m)
Total Stockholder Equity = 663.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.81% (Net Income 501.0m / Total Assets 13.55b)
RoE = 75.54% (Net Income TTM 501.0m / Total Stockholder Equity 663.2m)
RoCE = 12.93% (EBIT 1.22b / Capital Employed (Equity 663.2m + L.T.Debt 8.78b))
RoIC = 8.42% (NOPAT 804.0m / Invested Capital 9.55b)
WACC = 2.61% (E(2.22b)/V(11.05b) * Re(9.21%) + D(8.83b)/V(11.05b) * Rd(1.45%) * (1-Tc(0.34)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.79%
[DCF Debug] Terminal Value 86.76% ; FCFF base≈604.0m ; Y1≈630.9m ; Y5≈728.8m
Fair Price DCF = 51.84 (EV 21.63b - Net Debt 8.16b = Equity 13.48b / Shares 260.0m; r=5.90% [WACC]; 5y FCF grow 4.76% → 2.90% )
EPS Correlation: -56.26 | EPS CAGR: -7.81% | SUE: 0.64 | # QB: 0
Revenue Correlation: 20.18 | Revenue CAGR: -0.02% | SUE: 0.72 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.95 | Chg30d=-0.059 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=3.84 | Chg30d=-0.119 | Revisions Net=-1 | Growth EPS=+1.9% | Growth Revenue=-1.7%